{"name":"Chiesi Farmaceutici","slug":"chiesi","ticker":"","exchange":"","domain":"chiesi.com","description":"Chiesi Farmaceutici S.p.A. is an Italian family controlled global pharmaceutical company based in Parma, Emilia-Romagna. Chiesi has 31 affiliates in the world, nearly 6,500 total employees and provides medicines to patients in 100 nations. Chiesi currently has revenues of 3 billion euros. According to 2020 official data from the European Patent Office (EPO), Chiesi Group, with 42 patents filed, is confirmed as the first Italian Pharmaceutical Company and third among Italian Companies across all sectors for filing the highest number of patents.","hq":"Parma, Italy","founded":0,"employees":"","ceo":"Giuseppe Accogli","sector":"Rare Disease / Respiratory / Neonatology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"Private","metrics":{"revenue":3200000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Kengreal","genericName":"CANGRELOR","slug":"cangrelor","revenue":200000000,"yoyGrowth":0,"percentOfTotal":61.3},{"name":"Juxtapid","genericName":"LOMITAPIDE","slug":"lomitapide","revenue":126000000,"yoyGrowth":0,"percentOfTotal":38.7}],"timeline":[{"date":"2008-01-01","label":"Cleviprex first approved","drug":"Cleviprex","drugSlug":"clevidipine","type":"approval","sentiment":"positive"},{"date":"2011-01-01","label":"Ferriprox first approved","drug":"Ferriprox","drugSlug":"deferiprone","type":"approval","sentiment":"positive"},{"date":"2012-01-01","label":"Juxtapid first approved","drug":"Juxtapid","drugSlug":"lomitapide","type":"approval","sentiment":"positive"},{"date":"2015-01-01","label":"Kengreal first approved","drug":"Kengreal","drugSlug":"cangrelor","type":"approval","sentiment":"positive"},{"date":"2023-01-01","label":"Elfabrio first approved","drug":"Elfabrio","drugSlug":"pegunigalsidase-alfa","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2038-10-25","label":"Ferriprox patent expiry (Method of Use)","drug":"Ferriprox","drugSlug":"deferiprone","type":"patent_expiry","sentiment":"negative"},{"date":"2038-10-25","label":"Ferriprox patent expiry (Method of Use)","drug":"Ferriprox","drugSlug":"deferiprone","type":"patent_expiry","sentiment":"negative"},{"date":"2038-10-25","label":"Ferriprox patent expiry (Formulation)","drug":"Ferriprox","drugSlug":"deferiprone","type":"patent_expiry","sentiment":"negative"},{"date":"2038-10-25","label":"Ferriprox patent expiry (Formulation)","drug":"Ferriprox","drugSlug":"deferiprone","type":"patent_expiry","sentiment":"negative"},{"date":"2038-10-25","label":"Ferriprox patent expiry (Formulation)","drug":"Ferriprox","drugSlug":"deferiprone","type":"patent_expiry","sentiment":"negative"},{"date":"2038-10-25","label":"Ferriprox patent expiry (Formulation)","drug":"Ferriprox","drugSlug":"deferiprone","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":200000000,"percentOfTotal":61.3,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Kengreal","genericName":"CANGRELOR","slug":"cangrelor","indication":"Percutaneous coronary intervention","status":"marketed","revenue":200000000},{"name":"CHF 5259","genericName":"CHF 5259","slug":"chf-5259","indication":"Atrial fibrillation for stroke prevention","status":"phase_2"},{"name":"Cleviprex","genericName":"CLEVIDIPINE","slug":"clevidipine","indication":"Hypertensive disorder","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":126000000,"percentOfTotal":38.7,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Juxtapid","genericName":"LOMITAPIDE","slug":"lomitapide","indication":"Familial hypercholesterolemia - homozygous","status":"marketed","revenue":126000000}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":52,"colorKey":"neuroscience","drugs":[{"name":"Atimos®","genericName":"Atimos®","slug":"atimos","indication":"Chronic obstructive pulmonary disease (COPD) maintenance therapy","status":"marketed"},{"name":"BDP DPI 2 months","genericName":"BDP DPI 2 months","slug":"bdp-dpi-2-months","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"BDP DPI and formoterol DPI","genericName":"BDP DPI and formoterol DPI","slug":"bdp-dpi-and-formoterol-dpi","indication":"Asthma maintenance therapy","status":"phase_2"},{"name":"BDP HFA 100 µg pMDI","genericName":"BDP HFA 100 µg pMDI","slug":"bdp-hfa-100-g-pmdi","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"BDP/FF + Tiotropium","genericName":"BDP/FF + Tiotropium","slug":"bdp-ff-tiotropium","indication":"Asthma (maintenance therapy)","status":"phase_3"},{"name":"BDP/FF/GB","genericName":"BDP/FF/GB","slug":"bdp-ff-gb","indication":"Chronic obstructive pulmonary disease (COPD)","status":"phase_3"},{"name":"BDP/Formoterol Next DPI","genericName":"BDP/Formoterol Next DPI","slug":"bdp-formoterol-next-dpi","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"BDP/salbutamol CFC pMDI","genericName":"BDP/salbutamol CFC pMDI","slug":"bdp-salbutamol-cfc-pmdi","indication":"Asthma maintenance and reliever therapy","status":"phase_3"},{"name":"BDP/salbutamol HFA pMDI","genericName":"BDP/salbutamol HFA pMDI","slug":"bdp-salbutamol-hfa-pmdi","indication":"Asthma maintenance and reliever therapy","status":"phase_3"},{"name":"Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium","genericName":"Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium","slug":"beclometasone-dipropionate-formoterol-fumarate-glycopyrronium","indication":"Chronic obstructive pulmonary disease (COPD) maintenance therapy","status":"phase_3"},{"name":"Beclometasone/Formoterol","genericName":"Beclometasone/Formoterol","slug":"beclometasone-formoterol","indication":"Asthma maintenance and reliever therapy","status":"marketed"},{"name":"Beclometasone/Formoterol/Glycopyrrolate","genericName":"Beclometasone/Formoterol/Glycopyrrolate","slug":"beclometasone-formoterol-glycopyrrolate","indication":"Chronic obstructive pulmonary disease (COPD) maintenance treatment","status":"phase_3"},{"name":"Beclomethasone (BDP)","genericName":"Beclomethasone (BDP)","slug":"beclomethasone-bdp","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium","genericName":"Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium","slug":"beclomethasone-dipropionate-formoterol-fumarate-glycopyrronium","indication":"Maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults","status":"phase_3"},{"name":"Beclomethasone dipropionate/Salbutamol combination","genericName":"Beclomethasone dipropionate/Salbutamol combination","slug":"beclomethasone-dipropionate-salbutamol-combination","indication":"Asthma maintenance and reliever therapy","status":"phase_3"},{"name":"Beclomethasone plus formoterol fixed combination","genericName":"Beclomethasone plus formoterol fixed combination","slug":"beclomethasone-plus-formoterol-fixed-combination","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"Budesonide 200 µg plus formoterol 6 µg DPI","genericName":"Budesonide 200 µg plus formoterol 6 µg DPI","slug":"budesonide-200-g-plus-formoterol-6-g-dpi","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"Budesonide extrafine pMDI","genericName":"Budesonide extrafine pMDI","slug":"budesonide-extrafine-pmdi","indication":"Maintenance treatment of asthma","status":"phase_2"},{"name":"CHF 1535","genericName":"CHF 1535","slug":"chf-1535","indication":"Chronic obstructive pulmonary disease (COPD) maintenance therapy","status":"phase_3"},{"name":"CHF 1535 100/6 NEXT DPI® 2 months","genericName":"CHF 1535 100/6 NEXT DPI® 2 months","slug":"chf-1535-100-6-next-dpi-2-months","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"CHF 1535 100/6 pMDI 2 months","genericName":"CHF 1535 100/6 pMDI 2 months","slug":"chf-1535-100-6-pmdi-2-months","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"CHF 1535 100/6 µg","genericName":"CHF 1535 100/6 µg","slug":"chf-1535-100-6-g","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"CHF 1535 200/6 µg","genericName":"CHF 1535 200/6 µg","slug":"chf-1535-200-6-g","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"CHF 1535 50/6µg","genericName":"CHF 1535 50/6µg","slug":"chf-1535-50-6-g","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"CHF 4226 pMDI","genericName":"CHF 4226 pMDI","slug":"chf-4226-pmdi","indication":"Chronic obstructive pulmonary disease (COPD) maintenance treatment","status":"phase_2"},{"name":"CHF 5993 100/6/12.5 µg","genericName":"CHF 5993 100/6/12.5 µg","slug":"chf-5993-100-6-12-5-g","indication":"Chronic obstructive pulmonary disease (COPD) maintenance therapy","status":"phase_3"},{"name":"CHF 5993 200/6/12.5 µg","genericName":"CHF 5993 200/6/12.5 µg","slug":"chf-5993-200-6-12-5-g","indication":"Chronic obstructive pulmonary disease (COPD) maintenance therapy","status":"phase_3"},{"name":"CHF 5993 DPI","genericName":"CHF 5993 DPI","slug":"chf-5993-dpi","indication":"Chronic obstructive pulmonary disease (COPD)","status":"phase_2"},{"name":"CHF 718 pMDI","genericName":"CHF 718 pMDI","slug":"chf-718-pmdi","indication":"Maintenance treatment of asthma","status":"phase_2"},{"name":"CHF1535","genericName":"CHF1535","slug":"chf1535","indication":"Asthma maintenance and reliever therapy","status":"marketed"},{"name":"CHF1535 200/6 µg pMDI","genericName":"CHF1535 200/6 µg pMDI","slug":"chf1535-200-6-g-pmdi","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"CHF1535 NEXT DPI","genericName":"CHF1535 NEXT DPI","slug":"chf1535-next-dpi","indication":"Chronic obstructive pulmonary disease (COPD) maintenance treatment","status":"phase_2"},{"name":"CHF1535 NEXThaler","genericName":"CHF1535 NEXThaler","slug":"chf1535-nexthaler","indication":"Chronic obstructive pulmonary disease (COPD)","status":"phase_2"},{"name":"CHF1535 pMDI","genericName":"CHF1535 pMDI","slug":"chf1535-pmdi","indication":"Maintenance and relief of asthma symptoms","status":"phase_2"},{"name":"CHF5993 pMDI","genericName":"CHF5993 pMDI","slug":"chf5993-pmdi","indication":"Maintenance treatment of asthma","status":"phase_2"},{"name":"CHF5993 pMDI with HFA-134a","genericName":"CHF5993 pMDI with HFA-134a","slug":"chf5993-pmdi-with-hfa-134a","indication":"Maintenance treatment of asthma","status":"phase_2"},{"name":"CHF6001 DPI","genericName":"CHF6001 DPI","slug":"chf6001-dpi","indication":"Chronic obstructive pulmonary disease (COPD)","status":"phase_2"},{"name":"Clenil® Modulite® via AeroChamber Plus™","genericName":"Clenil® Modulite® via AeroChamber Plus™","slug":"clenil-modulite-via-aerochamber-plus","indication":"Maintenance and relief of asthma symptoms","status":"phase_2"},{"name":"FlF/VI + Tiotropium","genericName":"FlF/VI + Tiotropium","slug":"flf-vi-tiotropium","indication":"Chronic obstructive pulmonary disease (COPD) maintenance therapy","status":"phase_3"},{"name":"Fluticasone plus salmeterol fixed combination","genericName":"Fluticasone plus salmeterol fixed combination","slug":"fluticasone-plus-salmeterol-fixed-combination","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"Formoterol 12 µg DPI","genericName":"Formoterol 12 µg DPI","slug":"formoterol-12-g-dpi","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"Formoterol Inhalation Solution","genericName":"Formoterol Inhalation Solution","slug":"formoterol-inhalation-solution","indication":"Chronic obstructive pulmonary disease (COPD)","status":"marketed"},{"name":"Formoterol powder 12 µg/unit dose","genericName":"Formoterol powder 12 µg/unit dose","slug":"formoterol-powder-12-g-unit-dose","indication":"Chronic obstructive pulmonary disease (COPD)","status":"phase_3"},{"name":"Foster BDP/Formoterol","genericName":"Foster BDP/Formoterol","slug":"foster-bdp-formoterol","indication":"Asthma maintenance therapy","status":"marketed"},{"name":"Foster® NEXThaler® 100/6 µg/unit dose","genericName":"Foster® NEXThaler® 100/6 µg/unit dose","slug":"foster-nexthaler-100-6-g-unit-dose","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"Glycopyrrolate + Formoterol","genericName":"Glycopyrrolate + Formoterol","slug":"glycopyrrolate-formoterol","indication":"Chronic obstructive pulmonary disease (COPD) maintenance therapy","status":"marketed"},{"name":"Poractant alfa (Curosurf®)","genericName":"Poractant alfa (Curosurf®)","slug":"poractant-alfa-curosurf","indication":"Respiratory distress syndrome (RDS) in premature infants","status":"marketed"},{"name":"Seretide Accuhaler® 500/50 µg/actuation","genericName":"Seretide Accuhaler® 500/50 µg/actuation","slug":"seretide-accuhaler-500-50-g-actuation","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"Seretide® Accuhaler® 250/50 µg/actuation","genericName":"Seretide® Accuhaler® 250/50 µg/actuation","slug":"seretide-accuhaler-250-50-g-actuation","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"beclomethasone/salbutamol combination","genericName":"beclomethasone/salbutamol combination","slug":"beclomethasone-salbutamol-combination","indication":"Maintenance and relief of asthma symptoms","status":"phase_3"},{"name":"budesonide plus formoterol combination","genericName":"budesonide plus formoterol combination","slug":"budesonide-plus-formoterol-combination","indication":"Maintenance and control of asthma symptoms","status":"phase_3"},{"name":"umeclidinium bromide and vilanterol trifenatate","genericName":"umeclidinium bromide and vilanterol trifenatate","slug":"umeclidinium-bromide-and-vilanterol-trifenatate","indication":"Chronic obstructive pulmonary disease (COPD) maintenance treatment","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":14,"colorKey":"cardiovascular","drugs":[{"name":"CHF 5259 12.5 µg","genericName":"CHF 5259 12.5 µg","slug":"chf-5259-12-5-g","indication":"Other","status":"phase_2"},{"name":"CHF 1535 Next DPI","genericName":"CHF 1535 Next DPI","slug":"chf-1535-next-dpi","indication":"Cystic fibrosis","status":"phase_2"},{"name":"CHF 1535 pMDI","genericName":"CHF 1535 pMDI","slug":"chf-1535-pmdi","indication":"Other","status":"phase_2"},{"name":"CHF 5188 pMDI","genericName":"CHF 5188 pMDI","slug":"chf-5188-pmdi","indication":"Other","status":"phase_2"},{"name":"CHF5259","genericName":"CHF5259","slug":"chf5259","indication":"Other","status":"phase_1"},{"name":"CHF5633","genericName":"CHF5633","slug":"chf5633","indication":"Treatment of cystic fibrosis","status":"phase_2"},{"name":"CHF5993","genericName":"CHF5993","slug":"chf5993","indication":"Other","status":"marketed"},{"name":"CHF6001","genericName":"CHF6001","slug":"chf6001","indication":"Other","status":"phase_2"},{"name":"CHF718 pMDI with HFA-134a","genericName":"CHF718 pMDI with HFA-134a","slug":"chf718-pmdi-with-hfa-134a","indication":"Other","status":"phase_2"},{"name":"Clenil® Modulite® via Volumatic™ spacer","genericName":"Clenil® Modulite® via Volumatic™ spacer","slug":"clenil-modulite-via-volumatic-spacer","indication":"Other","status":"phase_2"},{"name":"Ferriprox","genericName":"DEFERIPRONE","slug":"deferiprone","indication":"Iron overload","status":"marketed"},{"name":"Foster","genericName":"Foster","slug":"foster","indication":"Other","status":"marketed"},{"name":"Oleogel-S10","genericName":"Oleogel-S10","slug":"oleogel-s10","indication":"Acute wounds (cuts, abrasions, minor surgical wounds)","status":"phase_3"},{"name":"elapegademase-lvlr","genericName":"elapegademase-lvlr","slug":"elapegademase-lvlr","indication":"Other","status":"marketed"}]},{"name":"Rare Disease","slug":"rare-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"infectious","drugs":[{"name":"ELFABRIO","genericName":"PEGUNIGALSIDASE ALFA-IWXJ","slug":"pegunigalsidase-alfa-iwxj","indication":"Fabry's disease","status":"marketed"},{"name":"Elfabrio","genericName":"PEGUNIGALSIDASE ALFA","slug":"pegunigalsidase-alfa","indication":"Fabry's disease","status":"marketed"}]}],"pipeline":[{"name":"Kengreal","genericName":"CANGRELOR","slug":"cangrelor","phase":"marketed","mechanism":"Kengreal blocks the action of ADP on platelets, preventing platelet activation and aggregation.","indications":["Percutaneous coronary intervention"],"catalyst":""},{"name":"Juxtapid","genericName":"LOMITAPIDE","slug":"lomitapide","phase":"marketed","mechanism":"Juxtapid works by blocking the protein that helps transport cholesterol into the bloodstream.","indications":["Familial hypercholesterolemia - homozygous"],"catalyst":""},{"name":"CHF 5259 12.5 µg","genericName":"CHF 5259 12.5 µg","slug":"chf-5259-12-5-g","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Atimos®","genericName":"Atimos®","slug":"atimos","phase":"marketed","mechanism":"Atimos is a tiotropium bromide inhalation powder that acts as a long-acting anticholinergic (muscarinic antagonist) to relax airway smooth muscle and improve airflow in chronic obstructive pulmonary disease.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"BDP DPI 2 months","genericName":"BDP DPI 2 months","slug":"bdp-dpi-2-months","phase":"phase_3","mechanism":"BDP (beclomethasone dipropionate) is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in the lungs.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"BDP DPI and formoterol DPI","genericName":"BDP DPI and formoterol DPI","slug":"bdp-dpi-and-formoterol-dpi","phase":"phase_2","mechanism":"This combination inhaler delivers beclomethasone dipropionate (a corticosteroid) and formoterol (a long-acting beta-2 agonist) to reduce airway inflammation and improve bronchial smooth muscle relaxation in obstructive airway diseases.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"BDP HFA 100 µg pMDI","genericName":"BDP HFA 100 µg pMDI","slug":"bdp-hfa-100-g-pmdi","phase":"phase_3","mechanism":"BDP (beclomethasone dipropionate) is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in the lungs.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"BDP/FF + Tiotropium","genericName":"BDP/FF + Tiotropium","slug":"bdp-ff-tiotropium","phase":"phase_3","mechanism":"BDP/FF (beclomethasone/formoterol) is an inhaled corticosteroid plus long-acting beta-2 agonist combination that reduces airway inflammation and bronchospasm, while tiotropium is a long-acting muscarinic antagonist that provides sustained bronchodilation.","indications":["Asthma (maintenance therapy)","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"BDP/FF/GB","genericName":"BDP/FF/GB","slug":"bdp-ff-gb","phase":"phase_3","mechanism":"BDP/FF/GB is a triple-combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist that reduces airway inflammation and improves bronchodilation through multiple pathways.","indications":["Chronic obstructive pulmonary disease (COPD)","Asthma (potential indication under investigation)"],"catalyst":""},{"name":"BDP/Formoterol Next DPI","genericName":"BDP/Formoterol Next DPI","slug":"bdp-formoterol-next-dpi","phase":"phase_3","mechanism":"BDP/Formoterol combines an inhaled corticosteroid (beclomethasone dipropionate) with a long-acting beta-2 agonist (formoterol) to reduce airway inflammation and improve bronchial smooth muscle relaxation.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"BDP/salbutamol CFC pMDI","genericName":"BDP/salbutamol CFC pMDI","slug":"bdp-salbutamol-cfc-pmdi","phase":"phase_3","mechanism":"BDP/salbutamol is a combination inhaler that reduces airway inflammation via corticosteroid action while providing rapid bronchodilation through beta-2 agonist stimulation.","indications":["Asthma maintenance and reliever therapy","Chronic obstructive pulmonary disease (COPD) with reversible airflow obstruction"],"catalyst":""},{"name":"BDP/salbutamol HFA pMDI","genericName":"BDP/salbutamol HFA pMDI","slug":"bdp-salbutamol-hfa-pmdi","phase":"phase_3","mechanism":"BDP/salbutamol is a combination inhaler that reduces airway inflammation via corticosteroid action while providing rapid bronchodilation through beta-2 agonist stimulation.","indications":["Asthma maintenance and reliever therapy","Chronic obstructive pulmonary disease (COPD) with reversible airflow obstruction"],"catalyst":""},{"name":"Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium","genericName":"Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium","slug":"beclometasone-dipropionate-formoterol-fumarate-glycopyrronium","phase":"phase_3","mechanism":"This triple-combination inhaler delivers a corticosteroid to reduce airway inflammation, a long-acting beta-2 agonist to relax airway smooth muscle, and an anticholinergic to further dilate airways.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance therapy","Asthma maintenance therapy (in select populations)"],"catalyst":""},{"name":"Beclometasone/Formoterol","genericName":"Beclometasone/Formoterol","slug":"beclometasone-formoterol","phase":"marketed","mechanism":"Beclometasone is a corticosteroid that reduces airway inflammation, while formoterol is a long-acting beta-2 agonist that relaxes bronchial smooth muscle, together providing anti-inflammatory and bronchodilatory effects.","indications":["Asthma maintenance and reliever therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Beclometasone/Formoterol/Glycopyrrolate","genericName":"Beclometasone/Formoterol/Glycopyrrolate","slug":"beclometasone-formoterol-glycopyrrolate","phase":"phase_3","mechanism":"This triple-combination inhaler delivers a corticosteroid (beclometasone) to reduce airway inflammation, a long-acting beta-2 agonist (formoterol) to dilate airways, and an anticholinergic (glycopyrrolate) to further relax airway smooth muscle.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance treatment"],"catalyst":""},{"name":"Beclomethasone (BDP)","genericName":"Beclomethasone (BDP)","slug":"beclomethasone-bdp","phase":"phase_3","mechanism":"Beclomethasone is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors in the lungs.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium","genericName":"Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium","slug":"beclomethasone-dipropionate-formoterol-fumarate-glycopyrronium","phase":"phase_3","mechanism":"This triple-combination inhaler delivers a corticosteroid to reduce airway inflammation, a long-acting beta-2 agonist to relax airway smooth muscle, and an anticholinergic to further dilate airways.","indications":["Maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults"],"catalyst":""},{"name":"Beclomethasone dipropionate/Salbutamol combination","genericName":"Beclomethasone dipropionate/Salbutamol combination","slug":"beclomethasone-dipropionate-salbutamol-combination","phase":"phase_3","mechanism":"This combination inhaler delivers a corticosteroid to reduce airway inflammation and a short-acting beta-2 agonist to rapidly relax bronchial smooth muscle.","indications":["Asthma maintenance and reliever therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Beclomethasone plus formoterol fixed combination","genericName":"Beclomethasone plus formoterol fixed combination","slug":"beclomethasone-plus-formoterol-fixed-combination","phase":"phase_3","mechanism":"Beclomethasone (a corticosteroid) reduces airway inflammation while formoterol (a long-acting beta-2 agonist) relaxes airway smooth muscle to improve breathing.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Budesonide 200 µg plus formoterol 6 µg DPI","genericName":"Budesonide 200 µg plus formoterol 6 µg DPI","slug":"budesonide-200-g-plus-formoterol-6-g-dpi","phase":"phase_3","mechanism":"Budesonide reduces airway inflammation while formoterol relaxes airway smooth muscle, together improving airflow and reducing asthma/COPD symptoms.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"Budesonide extrafine pMDI","genericName":"Budesonide extrafine pMDI","slug":"budesonide-extrafine-pmdi","phase":"phase_2","mechanism":"Budesonide extrafine pMDI is a corticosteroid that works by reducing inflammation in the lungs.","indications":["Maintenance treatment of asthma","Maintenance treatment of COPD"],"catalyst":""},{"name":"CHF 1535","genericName":"CHF 1535","slug":"chf-1535","phase":"phase_3","mechanism":"CHF 1535 is a dual bronchodilator that combines a long-acting beta-2 agonist with a long-acting muscarinic antagonist to improve airway function in chronic obstructive pulmonary disease.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"CHF 1535 100/6 NEXT DPI® 2 months","genericName":"CHF 1535 100/6 NEXT DPI® 2 months","slug":"chf-1535-100-6-next-dpi-2-months","phase":"phase_3","mechanism":"CHF 1535 is a fixed-dose combination of beclomethasone dipropionate and formoterol fumarate delivered via a dry powder inhaler for maintenance treatment of asthma and COPD.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"CHF 1535 100/6 pMDI 2 months","genericName":"CHF 1535 100/6 pMDI 2 months","slug":"chf-1535-100-6-pmdi-2-months","phase":"phase_3","mechanism":"CHF 1535 is a fixed-dose combination inhaled corticosteroid and long-acting beta-2 agonist that reduces airway inflammation and improves bronchodilation in respiratory disease.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"CHF 1535 100/6 µg","genericName":"CHF 1535 100/6 µg","slug":"chf-1535-100-6-g","phase":"phase_3","mechanism":"CHF 1535 is a fixed-dose combination inhaled corticosteroid and long-acting beta-2 agonist that reduces airway inflammation and improves bronchodilation in respiratory disease.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"CHF 1535 200/6 µg","genericName":"CHF 1535 200/6 µg","slug":"chf-1535-200-6-g","phase":"phase_3","mechanism":"CHF 1535 is a fixed-dose combination inhaled corticosteroid and long-acting beta-2 agonist that reduces airway inflammation and improves bronchodilation in respiratory disease.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"CHF 1535 50/6µg","genericName":"CHF 1535 50/6µg","slug":"chf-1535-50-6-g","phase":"phase_3","mechanism":"CHF 1535 is a fixed-dose combination inhaled corticosteroid and long-acting beta-2 agonist that reduces airway inflammation and improves bronchodilation in respiratory disease.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"CHF 1535 Next DPI","genericName":"CHF 1535 Next DPI","slug":"chf-1535-next-dpi","phase":"phase_2","mechanism":"CHF 1535 Next DPI is a dry powder inhaler for the treatment of cystic fibrosis.","indications":["Cystic fibrosis"],"catalyst":""},{"name":"CHF 1535 pMDI","genericName":"CHF 1535 pMDI","slug":"chf-1535-pmdi","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CHF 4226 pMDI","genericName":"CHF 4226 pMDI","slug":"chf-4226-pmdi","phase":"phase_2","mechanism":"CHF 4226 is an inhaled dual bronchodilator combining a long-acting beta-2 agonist and long-acting muscarinic antagonist for maintenance treatment of chronic obstructive pulmonary disease.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance treatment"],"catalyst":""},{"name":"CHF 5188 pMDI","genericName":"CHF 5188 pMDI","slug":"chf-5188-pmdi","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CHF 5259","genericName":"CHF 5259","slug":"chf-5259","phase":"phase_2","mechanism":"CHF 5259 is a small molecule drug that acts as a selective inhibitor of the sodium-activated potassium channel, KCNN4.","indications":["Atrial fibrillation for stroke prevention"],"catalyst":""},{"name":"CHF 5993 100/6/12.5 µg","genericName":"CHF 5993 100/6/12.5 µg","slug":"chf-5993-100-6-12-5-g","phase":"phase_3","mechanism":"CHF 5993 is a triple-combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist that reduces airway inflammation and improves bronchodilation through multiple pathways.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance therapy","Asthma maintenance therapy (potential)"],"catalyst":""},{"name":"CHF 5993 200/6/12.5 µg","genericName":"CHF 5993 200/6/12.5 µg","slug":"chf-5993-200-6-12-5-g","phase":"phase_3","mechanism":"CHF 5993 is a triple-combination inhaled therapy that combines a long-acting beta-2 agonist, long-acting muscarinic antagonist, and inhaled corticosteroid to improve airway function and reduce inflammation in chronic obstructive pulmonary disease.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"CHF 5993 DPI","genericName":"CHF 5993 DPI","slug":"chf-5993-dpi","phase":"phase_2","mechanism":"CHF 5993 DPI is a dry powder inhaler formulation of a specific drug.","indications":["Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"CHF 718 pMDI","genericName":"CHF 718 pMDI","slug":"chf-718-pmdi","phase":"phase_2","mechanism":"CHF 718 pMDI is a corticosteroid used to reduce inflammation in the airways.","indications":["Maintenance treatment of asthma","Treatment of chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"CHF1535","genericName":"CHF1535","slug":"chf1535","phase":"marketed","mechanism":"CHF1535 is a fixed-dose combination of beclomethasone dipropionate and formoterol fumarate that reduces airway inflammation and provides bronchodilation for respiratory disease management.","indications":["Asthma maintenance and reliever therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"CHF1535 200/6 µg pMDI","genericName":"CHF1535 200/6 µg pMDI","slug":"chf1535-200-6-g-pmdi","phase":"phase_3","mechanism":"CHF1535 is a fixed-dose combination of beclomethasone dipropionate (ICS) and formoterol (LABA) that reduces airway inflammation and improves bronchial smooth muscle relaxation.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"CHF1535 NEXT DPI","genericName":"CHF1535 NEXT DPI","slug":"chf1535-next-dpi","phase":"phase_2","mechanism":"CHF1535 is a dual bronchodilator combining an inhaled corticosteroid with a long-acting beta-2 agonist and long-acting muscarinic antagonist for maintenance treatment of chronic obstructive pulmonary disease.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance treatment"],"catalyst":""},{"name":"CHF1535 NEXThaler","genericName":"CHF1535 NEXThaler","slug":"chf1535-nexthaler","phase":"phase_2","mechanism":"CHF1535 NEXThaler is a dry powder inhaler delivering a fixed dose of a combination of fluticasone furoate and umeclidinium","indications":["Chronic obstructive pulmonary disease (COPD)","Asthma"],"catalyst":""},{"name":"CHF1535 pMDI","genericName":"CHF1535 pMDI","slug":"chf1535-pmdi","phase":"phase_2","mechanism":"CHF1535 pMDI is a corticosteroid inhalation powder.","indications":["Maintenance and relief of asthma symptoms","Maintenance treatment of COPD symptoms"],"catalyst":""},{"name":"CHF5259","genericName":"CHF5259","slug":"chf5259","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CHF5633","genericName":"CHF5633","slug":"chf5633","phase":"phase_2","mechanism":"CHF5633 is a small molecule in development for the treatment of cystic fibrosis.","indications":["Treatment of cystic fibrosis"],"catalyst":""},{"name":"CHF5993","genericName":"CHF5993","slug":"chf5993","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CHF5993 pMDI","genericName":"CHF5993 pMDI","slug":"chf5993-pmdi","phase":"phase_2","mechanism":"CHF5993 pMDI is a corticosteroid inhalation powder for the maintenance treatment of asthma and the treatment of chronic obstructive pulmonary disease (COPD).","indications":["Maintenance treatment of asthma","Treatment of chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"CHF5993 pMDI with HFA-134a","genericName":"CHF5993 pMDI with HFA-134a","slug":"chf5993-pmdi-with-hfa-134a","phase":"phase_2","mechanism":"CHF5993 pMDI with HFA-134a is a pressurized metered-dose inhaler formulation of a corticosteroid.","indications":["Maintenance treatment of asthma","Maintenance treatment of COPD"],"catalyst":""},{"name":"CHF6001","genericName":"CHF6001","slug":"chf6001","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CHF6001 DPI","genericName":"CHF6001 DPI","slug":"chf6001-dpi","phase":"phase_2","mechanism":"CHF6001 DPI is a dry powder inhaler formulation of a long-acting muscarinic antagonist.","indications":["Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"CHF718 pMDI with HFA-134a","genericName":"CHF718 pMDI with HFA-134a","slug":"chf718-pmdi-with-hfa-134a","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Clenil® Modulite® via AeroChamber Plus™","genericName":"Clenil® Modulite® via AeroChamber Plus™","slug":"clenil-modulite-via-aerochamber-plus","phase":"phase_2","mechanism":"Clenil Modulite is a corticosteroid that reduces inflammation in the airways.","indications":["Maintenance and relief of asthma symptoms","Maintenance treatment of chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Clenil® Modulite® via Volumatic™ spacer","genericName":"Clenil® Modulite® via Volumatic™ spacer","slug":"clenil-modulite-via-volumatic-spacer","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cleviprex","genericName":"CLEVIDIPINE","slug":"clevidipine","phase":"marketed","mechanism":"Cleviprex works by blocking calcium channels in blood vessel walls, causing them to relax and lower blood pressure.","indications":["Hypertensive disorder"],"catalyst":""},{"name":"ELFABRIO","genericName":"PEGUNIGALSIDASE ALFA-IWXJ","slug":"pegunigalsidase-alfa-iwxj","phase":"marketed","mechanism":"","indications":["Fabry's disease"],"catalyst":""},{"name":"Elfabrio","genericName":"PEGUNIGALSIDASE ALFA","slug":"pegunigalsidase-alfa","phase":"marketed","mechanism":"Elfabrio works by reducing the accumulation of a specific lipid in the body.","indications":["Fabry's disease"],"catalyst":""},{"name":"Ferriprox","genericName":"DEFERIPRONE","slug":"deferiprone","phase":"marketed","mechanism":"Ferriprox works by binding to iron in the body and removing it, thereby reducing iron overload.","indications":["Iron overload","beta Thalassemia"],"catalyst":""},{"name":"FlF/VI + Tiotropium","genericName":"FlF/VI + Tiotropium","slug":"flf-vi-tiotropium","phase":"phase_3","mechanism":"FlF/VI is a fixed-dose combination of fluticasone furoate and vilanterol (long-acting beta-2 agonist and inhaled corticosteroid) combined with tiotropium (long-acting muscarinic antagonist) to provide multi-mechanism bronchodilation and anti-inflammatory effects in chronic obstructive pulmonary disease.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"Fluticasone plus salmeterol fixed combination","genericName":"Fluticasone plus salmeterol fixed combination","slug":"fluticasone-plus-salmeterol-fixed-combination","phase":"phase_3","mechanism":"Fluticasone (a corticosteroid) reduces airway inflammation while salmeterol (a long-acting beta-2 agonist) relaxes airway smooth muscle to improve breathing.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"Formoterol 12 µg DPI","genericName":"Formoterol 12 µg DPI","slug":"formoterol-12-g-dpi","phase":"phase_3","mechanism":"Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"Formoterol Inhalation Solution","genericName":"Formoterol Inhalation Solution","slug":"formoterol-inhalation-solution","phase":"marketed","mechanism":"Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.","indications":["Chronic obstructive pulmonary disease (COPD)","Asthma (maintenance therapy)"],"catalyst":""},{"name":"Formoterol powder 12 µg/unit dose","genericName":"Formoterol powder 12 µg/unit dose","slug":"formoterol-powder-12-g-unit-dose","phase":"phase_3","mechanism":"Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing bronchodilation and improved airflow.","indications":["Chronic obstructive pulmonary disease (COPD)","Asthma (maintenance therapy)"],"catalyst":""},{"name":"Foster","genericName":"Foster","slug":"foster","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Foster BDP/Formoterol","genericName":"Foster BDP/Formoterol","slug":"foster-bdp-formoterol","phase":"marketed","mechanism":"Foster combines beclomethasone dipropionate (a corticosteroid) and formoterol (a long-acting beta-2 agonist) to reduce airway inflammation and dilate airways in asthma and COPD.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"Foster® NEXThaler® 100/6 µg/unit dose","genericName":"Foster® NEXThaler® 100/6 µg/unit dose","slug":"foster-nexthaler-100-6-g-unit-dose","phase":"phase_3","mechanism":"Foster NEXThaler combines beclomethasone dipropionate (an inhaled corticosteroid) and formoterol (a long-acting beta-2 agonist) to reduce airway inflammation and improve bronchial smooth muscle relaxation in asthma and COPD.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"Glycopyrrolate + Formoterol","genericName":"Glycopyrrolate + Formoterol","slug":"glycopyrrolate-formoterol","phase":"marketed","mechanism":"Glycopyrrolate is an anticholinergic agent that blocks muscarinic receptors to reduce airway secretions and bronchoconstriction, while formoterol is a long-acting beta-2 agonist that relaxes airway smooth muscle.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"Oleogel-S10","genericName":"Oleogel-S10","slug":"oleogel-s10","phase":"phase_3","mechanism":"Oleogel-S10 is a topical oleogel formulation containing birch bark extract that promotes wound healing and tissue repair through anti-inflammatory and antimicrobial properties.","indications":["Acute wounds (cuts, abrasions, minor surgical wounds)","Chronic wounds and ulcers"],"catalyst":""},{"name":"Poractant alfa (Curosurf®)","genericName":"Poractant alfa (Curosurf®)","slug":"poractant-alfa-curosurf","phase":"marketed","mechanism":"Poractant alfa is a natural pulmonary surfactant that reduces surface tension in the lungs and restores normal respiratory function in neonates with respiratory distress syndrome.","indications":["Respiratory distress syndrome (RDS) in premature infants","Meconium aspiration syndrome (MAS) in neonates"],"catalyst":""},{"name":"Seretide Accuhaler® 500/50 µg/actuation","genericName":"Seretide Accuhaler® 500/50 µg/actuation","slug":"seretide-accuhaler-500-50-g-actuation","phase":"phase_3","mechanism":"Seretide combines a long-acting beta-2 agonist (salmeterol) and an inhaled corticosteroid (fluticasone propionate) to relax airway smooth muscle and reduce airway inflammation.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"Seretide® Accuhaler® 250/50 µg/actuation","genericName":"Seretide® Accuhaler® 250/50 µg/actuation","slug":"seretide-accuhaler-250-50-g-actuation","phase":"phase_3","mechanism":"Seretide combines a long-acting beta-2 agonist (salmeterol) and an inhaled corticosteroid (fluticasone propionate) to relax airway smooth muscle and reduce airway inflammation.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"beclomethasone/salbutamol combination","genericName":"beclomethasone/salbutamol combination","slug":"beclomethasone-salbutamol-combination","phase":"phase_3","mechanism":"Beclomethasone is a corticosteroid that reduces inflammation, while salbutamol is a beta-2 adrenergic receptor agonist that relaxes airway smooth muscle.","indications":["Maintenance and relief of asthma symptoms","Maintenance and relief of chronic obstructive pulmonary disease (COPD) symptoms"],"catalyst":""},{"name":"budesonide plus formoterol combination","genericName":"budesonide plus formoterol combination","slug":"budesonide-plus-formoterol-combination","phase":"phase_3","mechanism":"Budesonide is a corticosteroid that reduces inflammation, while formoterol is a long-acting beta2-adrenergic receptor agonist that relaxes airway muscles.","indications":["Maintenance and control of asthma symptoms","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"elapegademase-lvlr","genericName":"elapegademase-lvlr","slug":"elapegademase-lvlr","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"umeclidinium bromide and vilanterol trifenatate","genericName":"umeclidinium bromide and vilanterol trifenatate","slug":"umeclidinium-bromide-and-vilanterol-trifenatate","phase":"marketed","mechanism":"Umeclidinium is a long-acting muscarinic antagonist and vilanterol is a long-acting beta-2 agonist that together relax airway smooth muscle and improve airflow in chronic obstructive pulmonary disease.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance treatment"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQTzFTR2tJTnhWWHhpOEloZXo3X3MyUGlsUkNkZTE0aXU2Z0Z3dTNiN2JCcFpqdG9qT1FHQjRET2p6UGdWRDZXSVlpTWlZQ3NKM0tyUVNPOFFzRnkzTEJLZGoyNGhkUmkyX01lYzI3Nll3ZGowNzVySktsUm4ySERuSTU1WWhxNHlidGJOQUVXWnFKR2xmaU1tb0xxTFMybEpOYnFMRU44UkNYcFcyN3QtX0ZWanYtSnBob1E?oc=5","date":"2026-02-20","type":"earnings","source":"Statista","summary":"Annual revenue of the Italian pharmaceutical company Chiesi from 2009 to 2023 - Statista","headline":"Annual revenue of the Italian pharmaceutical company Chiesi from 2009 to 2023","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE1IV2poQzRVR1NZaXR6c1lWT1QyUE9fTlJXbjdUMmNDSzJfMUIzczFnY29YQ0hRUVhsNkhObGUwWlUtNEhOMThvSEc5WGplbHRRNXB4MFl4bFQ2dVJxbVJFQllpR3dMX1RiTkRjcFFZM2dwRTdPX0xR?oc=5","date":"2026-01-26","type":"pipeline","source":"Il Sole 24 ORE","summary":"For the drug industry the boost of made in Italy - Il Sole 24 ORE","headline":"For the drug industry the boost of made in Italy - Il Sole 24 ORE","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNa1VEZmpOZWJOVlFFMGNLRDV2elp5WnYtanJHQWlYOFpIWkFVaFphTHRWaUY3R3RKZDQxNWNBamhzaHlvWW1ZOG9sS1JLVVRWVlNHNkthQi1YMGowVFNOVXh5bHB0emJiUENYcHY2clZtSmtONkthblMwX1VpTHlxNmhrWVU4ekROZGRLNGJIMDNJY3BvWnYzZnhGWkVEVENFamwtSkdoMGg2d2J4NTE5RkZvOA?oc=5","date":"2025-10-06","type":"deal","source":"Fierce Biotech","summary":"Chiesi fertilizes Arbor's rare disease gene therapy efforts with $2B biobucks deal - Fierce Biotech","headline":"Chiesi fertilizes Arbor's rare disease gene therapy efforts with $2B biobucks deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxOUktUeWRudnlKdWw5V2EybjRQZ1o1M3BjMXY1UnBZZ2pobDZtLU1CY25xQ0MwanQzSjFNczhjMjhERUt5T3BqckN0REUteHM5bjBXdVNvSnZKd25nSzZVS25pbUVVVHk3UjdVV0FFRDhjaF9RWl9DY1haVEMzRlh1dExxMVNrQ014MWFKeHRSMWRWRzlmbkJkNUlkVVYtWEgxWDNuSzMxckFfWDFxOEc1ellIM2JfSlhlVFR6S3UyS195UGk5LVNvVDZZSlAxb2JpdW01aENuYVNkUDNlNGZV?oc=5","date":"2025-06-05","type":"pipeline","source":"Reuters","summary":"Italy's Chiesi Group plans acquisitions to boost sales to 6 billion euros by 2030 - Reuters","headline":"Italy's Chiesi Group plans acquisitions to boost sales to 6 billion euros by 2030","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5sYWQ4Ykt4WWdZMEhnRFNnRzZjem1KTWhIbU55MUF4dk9OU0pBYS1vdFU1Rk9Ub1Z5WkxBMG5JbjFaMnNBZGk0NkVPcmpBZHpVZW5BU0ZOSWgtNFEycVlERGxtQkgtck5Kd3RSWXZn?oc=5","date":"2023-07-24","type":"pipeline","source":"KED Global","summary":"Kwangdong to sell exclusively three global rare disease drugs - KED Global","headline":"Kwangdong to sell exclusively three global rare disease drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPenExaXpPQ0I0aDluMl9MTXQ2V1p4ajlrUkxnOVZaRmJ3SmdGVFlwYWFqcFBZdW51RTBveVpzZ0xydGVzdFJURHVwcHVPNjdNdjRIRjJYNmxISUJSYkswdlBwQUZ1N25HV1lheENfelZNOERaeFhpVmpvak5oVEtlRXFRV2Y2VEp5cmJVOExwWlBXYkdSel80T1YyUTZ5eTk1RW9DTGYtekd4SlpRMkZlOWVDU0NPaDAzZnZhcm1QYw?oc=5","date":"2023-04-12","type":"deal","source":"drugdiscoverytrends.com","summary":"Chiesi acquires Amryt pharma to boost rare disease therapy focus - drugdiscoverytrends.com","headline":"Chiesi acquires Amryt pharma to boost rare disease therapy focus","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOVmVGSEhGMl9nTjk0Nm4zT1g5ZDNGdDVWWFkwbXJodVY0Y0l3bDJNX3dOVVFXVWFIdVVkWEVnRTJEVEpZQTJTSXo4ODdtUUhfRlVDalNJeTM3NkJsV3lYWUpzMzNmMm1CNlItTlJXRXphZU1saGQtMDAyYUNicmRTWGZkV1l5RkV3NGthMkhTU1l2dw?oc=5","date":"2023-01-09","type":"deal","source":"Yahoo Finance","summary":"Italian Privately Held Chiesi Farmaceutici To Acquire Amryt Pharma For $1.25B - Yahoo Finance","headline":"Italian Privately Held Chiesi Farmaceutici To Acquire Amryt Pharma For $1.25B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE9sSjVBc2R0NXhGd3R0bDlRQUc0S0tFY1hzNmRHdGJqUkhuWTU2SGxCRFV4blYwQnY5clpNeVZiQXZUT0h2aXEwQ09BU1piS2NxMWpGTnRSS3pONkxhZDBTLWZJa0ZNZU5xZ1dBcGRHQ0FmYjlRaUowZmRGdw?oc=5","date":"2023-01-09","type":"deal","source":"Pharmaceutical Technology","summary":"Chiesi Farmaceutici agrees to buy Amryt Pharma for $1.48bn - Pharmaceutical Technology","headline":"Chiesi Farmaceutici agrees to buy Amryt Pharma for $1.48bn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPZ0pjNHgybmFKbzdZTk1oaGdGd2pQZHFNZ09LOHNpU0hMQkRQUzcxZ2JuZGw0ZHB5ME9oV1QyTnNSN2F1Q2hiaUhvOVE3QWI0c05ZNmpESG5EcDEybkxXOHBzZG5hUlhMd3NNNzljbWE1Y2tTSVpadVQ1QTVWMnFnSE93SF9vRkFJSFpUYV93?oc=5","date":"2023-01-09","type":"deal","source":"Fierce Pharma","summary":"JPM23: Chiesi gets jump-start on JPM buzz with $1.48B Amryt buyout - Fierce Pharma","headline":"JPM23: Chiesi gets jump-start on JPM buzz with $1.48B Amryt buyout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPUWxVRWhwLXpoVmMyTER0WkxNYllpd1hSb2dxTGVsaGVPWnBEeVk0bDdfSWZ6ZFN4VnhSOEFfZzVHandZUEs5b1JsLUpmVzhTa3I3NFdhUGV5LVVRREtqOFJYTkJsNmRkRjhwMFpnOVZQUU5XMHlXX0tuWWk3WlFPeXlCb09ZRVU5ZEE?oc=5","date":"2023-01-09","type":"pipeline","source":"BioSpace","summary":"Chiesi Ups Rare Disease Game with $1.48B Amryt Acquisition - BioSpace","headline":"Chiesi Ups Rare Disease Game with $1.48B Amryt Acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQQ3FzcmM3TGRBa09XSkp6TXYxYlZxRE0yaUlLSWs2eDg2dFNycnllUGJnYWpUc3BGWTEwUkFWc3FOcVhtX1haWWJSUDNCTGlaMEl4TTh2U1MySDI4TG9FUW1KdHdQY2V5TTQwQk9mMzRDeWtVazBPdHNNS003a1lnejlPSldwRTl5dEtLTVJBUndBNFNaQjBPdzh3XzVyTjNzWHlFMExpajdGekdXUG53UlFaVW1iMU5sOFY4RF9MY2tvZ0U?oc=5","date":"2023-01-08","type":"deal","source":"GlobeNewswire","summary":"Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc - GlobeNewswire","headline":"Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQXzdFeFhqeFo2Wm5aX04wQWs1cTJpYWg3RHdpYXU0dDdFcWVoRHZHcTltektNOHlCS09IRmdxejgyMkhJN2VYWkhTTlVnbThYUGhOeG82Z25MS0p2OHhBMGJjQjdzcmFrT2ZjSE92NGFRRWY0ZUJ4cTVzSGhHOUNmbURkS0lNS2o2eXFzU1llTG5icVFURkM5N3pTWU13MllOY1NMLUlCS3doRmxCWjdJajA1ajRFQmhXaDFaM0p3?oc=5","date":"2022-11-25","type":"pipeline","source":"pharmaphorum","summary":"Touring Chiesi's vision for the future at the new Biotech Centre of Excellence - pharmaphorum","headline":"Touring Chiesi's vision for the future at the new Biotech Centre of Excellence","sentiment":"neutral"}],"patents":[{"drugName":"Ferriprox","drugSlug":"deferiprone","patentNumber":"11723874","type":"Method of Use","expiryDate":"2038-10-25","territory":"US","genericFilings":[]},{"drugName":"Ferriprox","drugSlug":"deferiprone","patentNumber":"11357731","type":"Method of Use","expiryDate":"2038-10-25","territory":"US","genericFilings":[]},{"drugName":"Ferriprox","drugSlug":"deferiprone","patentNumber":"10940115","type":"Formulation","expiryDate":"2038-10-25","territory":"US","genericFilings":[]},{"drugName":"Ferriprox","drugSlug":"deferiprone","patentNumber":"10780055","type":"Formulation","expiryDate":"2038-10-25","territory":"US","genericFilings":[]},{"drugName":"Ferriprox","drugSlug":"deferiprone","patentNumber":"11458103","type":"Formulation","expiryDate":"2038-10-25","territory":"US","genericFilings":[]},{"drugName":"Ferriprox","drugSlug":"deferiprone","patentNumber":"10940116","type":"Formulation","expiryDate":"2038-10-25","territory":"US","genericFilings":[]}],"drugCount":72,"phaseCounts":{"marketed":17,"phase_2":21,"phase_3":33,"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}